Clinical mutational profiling of PTOL tumors revealed the same frequency of oncogene (e.g. KRAS) and tumor suppressor gene (e.g. TP53) mutations as the general pancreatic cancer population (Table 1). This evidence concerns the gene KRAS and pancreatic neoplasm.